



## Press release

ZEISS TIVATO 700 and ZEISS EXTARO 300

### Inventor of ENT surgical microscopes heralds digital age in visualization

*TIVATO 700 and EXTARO 300 from ZEISS launch emerging workflow-enhancing augmentation concepts to ENT.*

Jena/Germany, Atlanta/USA, 7 October 2018.

At this year's AAO-HNSF Annual Meeting in Atlanta, USA, the ZEISS Medical Technology business segment presents its revolutionizing solutions for ENT (ear, nose and throat) surgery, TIVATO® 700 and EXTARO® 300. "With these brand new systems we offer ENT surgeons access to augmented visualization modalities beyond the white light and empower them to discover digital possibilities in their surgical specialty," says Dirk Brunner, Head of the Microsurgery Strategic Business Unit of ZEISS. Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec, adds, "The TIVATO 700 and EXTARO 300 will support our sales focus on the ENT segment, which has historically been a very important segment for the group, to give our customers technology ready for the future."

#### **ZEISS TIVATO 700: Transforming possibilities into realities**

Developed for demanding ENT surgical procedures, ZEISS TIVATO 700\* combines Workflow-Enhancing Visualization, Ultimate Reach & Flexibility and an All Digital approach for today's surgeons.

With **Workflow-Enhancing Visualization**, ZEISS TIVATO 700 makes available advanced **fluorescence options** for assessment of vessel patency and other applications. Integrated 4K technology allows surgeons to visualize procedures in brilliant image quality. At the same time, assistants, OR staff and observers benefit from the outstanding resolution and image quality while following the surgical intervention – for an invaluable learning and training experience.

Excellent overhead clearance, ultimate reach and an unparalleled working distance all contribute to giving surgeons **Ultimate Reach & Flexibility** to handle every OR situation with confidence. "We have been able to introduce robotic functionality into TIVATO 700 to support the stability of the system in clinical application through active vibration damping," states Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.



Today's ORs are becoming increasingly connected and the **All-Digital** approach ZEISS has taken with TIVATO 700 features an impressive, intuitive and easy-to-use graphical user interface: "The user interface felt natural. It wasn't like learning a new language; it felt more like an old friend that has been improved upon," says Dr. Sean McMenomey, Department of Otolaryngology-Head and Neck Surgery at Langone Health, New York City, USA. With a comprehensive connectivity package, ZEISS TIVATO 700 can be seamlessly integrated into a hospital's existing IT infrastructure. It supports data transfer and image documentation along the surgical workflow, and allows improved serviceability of the system via remote access delivered by ZEISS Smart Services.

### **ZEISS EXTARO 300: Boosting efficiency**

Designed for outpatient and basic ENT surgical procedures, ZEISS EXTARO 300 focuses on Augmented Visualization, Single-Handed Operation and Digital Data Management to help save valuable time before, during and after the surgical intervention.

New **Augmented Visualization** modalities of EXTARO 300, such as **NoGlare Mode** suppress obtrusive light reflections from wet tissue, or with **Multispectral Mode**, enhances the contrast between vasculature and tissue. These dedicated solutions help surgeons to confidently evaluate all situations without losing valuable information, which may be covered up by reflections or low color contrast. "I can see how in laryngology, in particular, some of those illumination modes will be particularly useful when looking at blood vessels on the larynx itself," says Dr. Peter A. Weisskopf, Mayo Clinic Phoenix.

Knowing that any adjustment to the visualization unit can interrupt the workflow, ZEISS EXTARO 300 has been designed to maneuver the system and control all its functions with a single hand. Controlling the light, camera and Varioskop® at the fingertips can help the surgeon perform procedures with maximum focus and efficiency.

In addition, ZEISS EXTARO 300 comes with the **ZEISS Connect App**, which provides a structured data management approach with easy organization of patient image and video data.

This integrated **Digital Data Management** supports clinical case documentation by conveniently integrating it into the digital practice.

"With these advances we support the entire ENT surgical segment with tailored offerings," summarizes Dr. Ludwin Monz.

\* Not available until conformity assessment according to MDD 93/42 is finished. Only for sale in selected countries. The shown contents may differ from the current status of approval of the product or service offering in your country.



**Ansprechpartner für die Presse**

Jochen Tham  
Director Marketing Communications Carl Zeiss Meditec AG  
Tel. 03641 220-331  
E-Mail: [press.meditec@zeiss.com](mailto:press.meditec@zeiss.com)

Sebastian Frericks  
Director Investor Relations Carl Zeiss Meditec AG  
Tel. 03641 220-116  
E-Mail: [investors.meditec@zeiss.com](mailto:investors.meditec@zeiss.com)

[www.zeiss.de/presse](http://www.zeiss.de/presse)

**Kurzprofil**

Carl Zeiss Meditec AG (ISIN: DE 0005313704), the ZEISS Medical Technology Segment, is listed on SDAX and TecDAX of the German stock exchange and one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,000 employees worldwide, the Group generated revenue of € 1,189.9 million in fiscal year 2016/17 (to 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

Weitere Informationen unter: [www.zeiss.de/med](http://www.zeiss.de/med)